Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor
- PMID: 34075224
- DOI: 10.1038/d41573-021-00098-4
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
